Boston Family Office LLC Increases Position in Stryker Corporation $SYK

Key Points

• Boston Family Office LLC increased its stake in Stryker Corporation by 3.4%, owning a total of 64,509 shares valued at approximately $24 million.
• Company Director Ronda E. Stryker sold 200,000 shares, reducing her holdings by 5.84% and retaining over 3.2 million shares valued at over $1.2 billion.
• Stryker Corporation reported earnings of $3.13 per share for the last quarter, exceeding analysts' expectations, and the company also announced a quarterly dividend of $0.84 per share.

Boston Family Office LLC increased its position in Stryker Corporation (NYSE:SYK - Free Report) by 3.4% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 64,509 shares of the medical technology company's stock after purchasing an additional 2,108 shares during the quarter. Stryker makes up about 1.7% of Boston Family Office LLC's investment portfolio, making the stock its 18th largest holding. Boston Family Office LLC's holdings in Stryker were worth $24,013,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Vanguard Group Inc. increased its holdings in shares of Stryker by 1.1% in the 1st quarter. Vanguard Group Inc. now owns 33,059,964 shares of the medical technology company's stock worth $12,306,572,000 after purchasing an additional 361,136 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Stryker by 0.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 11,109,722 shares of the medical technology company's stock valued at $4,000,056,000 after acquiring an additional 54,693 shares in the last quarter. Northern Trust Corp lifted its position in shares of Stryker by 13.2% in the fourth quarter. Northern Trust Corp now owns 3,606,237 shares of the medical technology company's stock valued at $1,298,426,000 after acquiring an additional 420,153 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Stryker by 13.1% in the first quarter. Goldman Sachs Group Inc. now owns 2,252,895 shares of the medical technology company's stock worth $838,640,000 after buying an additional 261,058 shares in the last quarter. Finally, GAMMA Investing LLC lifted its position in shares of Stryker by 43,226.8% in the first quarter. GAMMA Investing LLC now owns 2,074,922 shares of the medical technology company's stock worth $772,390,000 after buying an additional 2,070,133 shares in the last quarter. Hedge funds and other institutional investors own 77.09% of the company's stock.

Insiders Place Their Bets

In related news, Director Ronda E. Stryker sold 200,000 shares of the business's stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total value of $75,290,000.00. Following the completion of the sale, the director directly owned 3,222,108 shares of the company's stock, valued at $1,212,962,556.60. The trade was a 5.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 5.20% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

SYK has been the topic of several analyst reports. JMP Securities reissued a "market perform" rating on shares of Stryker in a research note on Monday, May 5th. Truist Financial set a $415.00 price objective on Stryker and gave the company a "hold" rating in a report on Monday, August 4th. Sanford C. Bernstein set a $450.00 target price on Stryker in a research report on Monday, May 5th. Needham & Company LLC increased their price target on Stryker from $442.00 to $448.00 and gave the stock a "buy" rating in a research report on Friday, August 1st. Finally, BTIG Research restated a "buy" rating on shares of Stryker in a research report on Monday, July 14th. Fifteen equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company's stock. According to MarketBeat.com, Stryker has a consensus rating of "Moderate Buy" and an average target price of $430.10.

Stryker Stock Up 0.7%

Shares of NYSE:SYK traded up $2.8360 during trading on Wednesday, hitting $392.7760. The company's stock had a trading volume of 841,647 shares, compared to its average volume of 1,435,260. The business has a 50 day moving average price of $386.87 and a two-hundred day moving average price of $379.45. The company has a market capitalization of $150.16 billion, a PE ratio of 52.07, a P/E/G ratio of 2.77 and a beta of 0.91. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78. Stryker Corporation has a fifty-two week low of $329.16 and a fifty-two week high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.13 EPS for the quarter, topping the consensus estimate of $3.07 by $0.06. The business had revenue of $6.02 billion during the quarter, compared to the consensus estimate of $5.92 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The company's quarterly revenue was up 11.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.81 earnings per share. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. As a group, research analysts expect that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be paid a dividend of $0.84 per share. The ex-dividend date is Tuesday, September 30th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.9%. Stryker's payout ratio is presently 44.50%.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.